Charles River Laboratories CRL Payments for Repurchase of Common Stock
Payments for Repurchase of Common Stock at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's payments for repurchase of common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's payments for repurchase of common stock?
- Charles River Laboratories (CRL) reported payments for repurchase of common stock of $208.29M in Q1 2026.
- How has Charles River Laboratories's payments for repurchase of common stock changed year-over-year?
- Charles River Laboratories's payments for repurchase of common stock decreased by 41.0% year-over-year, from $353.13M to $208.29M.
- What is the long-term trend for Charles River Laboratories's payments for repurchase of common stock?
- Over 4 years (2021 to 2025), Charles River Laboratories's payments for repurchase of common stock has grown at a 72.5% compound annual growth rate (CAGR), from $40.71M to $360.67M.
- What does payments for repurchase of common stock mean?
- The total cash spent by the company to buy back its own shares.
- How do you interpret payments for repurchase of common stock?
- Higher spending indicates a focus on returning capital to shareholders or confidence in the company's valuation, while lower spending may signal a need to preserve cash for operations or debt reduction.
- How does payments for repurchase of common stock compare across companies?
- Commonly reported by mature public companies as part of their capital return policy.